J I Bisson1, R van Deursen2, B Hannigan2, N Kitchiner3, K Barawi1, K Jones2, T Pickles4, J Skipper1, C Young5, L R Abbott2, M van Gelderen6, M J Nijdam7,8, E Vermetten6. 1. School of Medicine, Cardiff University, Cardiff, UK. 2. School of Healthcare Sciences, Cardiff University, Cardiff, UK. 3. Veterans' NHS Wales, Cardiff and Vale University Health Board, Cardiff, UK. 4. Centre for Trials Research, Cardiff University, Cardiff, UK. 5. Cardiff and Vale University Health Board, Cardiff, UK. 6. Department of Psychiatry, Leiden University Medical Center, Leiden, The Netherlands. 7. ARQ Centrum'45, ARQ National Psychotrauma Centre, Diemen, The Netherlands. 8. Department of Psychiatry, Amsterdam University Medical Centres, Amsterdam, The Netherlands.
Abstract
OBJECTIVE: To explore the potential efficacy of multi-modular motion-assisted memory desensitization and reprocessing (3MDR) in British military veterans with treatment-resistant service-related PTSD. METHODS: Exploratory single-blind, randomized, parallel arm, cross-over controlled trial with nested process evaluation to assess fidelity, adherence and factors that influence outcome. RESULTS: A total of 42 participants (all male) were randomized with 83% retention at 12 weeks and 86% at 26 weeks. The difference in mean Clinician-Administered PTSD Scale for DSM-5 scores between the immediate and delayed 3MDR arms was -9.38 (95% CI -17.33 to -1.44, P = 0.021) at 12 weeks and -3.59 (-14.39 to 7.20, P = 0.513) at 26 weeks when both groups had received 3MDR. The likely effect size of 3MDR was found to be 0.65. Improvements were maintained at 26-week follow-up. 3MDR was found to be acceptable to most, but not all, participants. Several factors that may impact efficacy and acceptability of 3MDR were identified. CONCLUSION:3MDR is a promising new intervention for treatment-resistant PTSD with emerging evidence of effect.
RCT Entities:
OBJECTIVE: To explore the potential efficacy of multi-modular motion-assisted memory desensitization and reprocessing (3MDR) in British military veterans with treatment-resistant service-related PTSD. METHODS: Exploratory single-blind, randomized, parallel arm, cross-over controlled trial with nested process evaluation to assess fidelity, adherence and factors that influence outcome. RESULTS: A total of 42 participants (all male) were randomized with 83% retention at 12 weeks and 86% at 26 weeks. The difference in mean Clinician-Administered PTSD Scale for DSM-5 scores between the immediate and delayed 3MDR arms was -9.38 (95% CI -17.33 to -1.44, P = 0.021) at 12 weeks and -3.59 (-14.39 to 7.20, P = 0.513) at 26 weeks when both groups had received 3MDR. The likely effect size of 3MDR was found to be 0.65. Improvements were maintained at 26-week follow-up. 3MDR was found to be acceptable to most, but not all, participants. Several factors that may impact efficacy and acceptability of 3MDR were identified. CONCLUSION: 3MDR is a promising new intervention for treatment-resistant PTSD with emerging evidence of effect.
Authors: Emily Tang; Chelsea Jones; Lorraine Smith-MacDonald; Matthew R G Brown; Eric H G J M Vermetten; Suzette Brémault-Phillips Journal: Int J Environ Res Public Health Date: 2021-11-22 Impact factor: 3.390
Authors: Tristin Hamilton; Lisa Burback; Lorraine Smith-MacDonald; Chelsea Jones; Matthew R G Brown; Cynthia Mikolas; Emily Tang; Kaitlin O'Toole; Priyanka Vergis; Anna Merino; Kyle Weiman; Eric H G J M Vermetten; Suzette Brémault-Phillips Journal: Front Psychiatry Date: 2021-12-22 Impact factor: 4.157
Authors: Chelsea Jones; Antonio Miguel Cruz; Lorraine Smith-MacDonald; Matthew R G Brown; Eric Vermetten; Suzette Brémault-Phillips Journal: JMIR Form Res Date: 2022-04-21
Authors: Chelsea Jones; Lorraine Smith-MacDonald; Matthew Robert Graham Brown; Ashley Pike; Eric Vermetten; Suzette Brémault-Phillips Journal: Brain Behav Date: 2022-07-18 Impact factor: 3.405